Find Clinical Trials

Inclusion Criteria: * Women, trans men, and non-binary people with female reproductive organs * ≥18 years at consent Exclusion Criteria: * Individuals who have previously undergone genetic testing for one or more of the following CSGs: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BRIP1, MLH1, MSH2, MSH6 * One or more first- or second-degree relative with a PV in any of above CSGs * Inability to provide informed consent

Inclusion Criteria: 1. Stroke Patients: * Diagnosed with stroke according to WHO criteria (≥20% disability rate documented in Adult Disability Health Board Report) * Having a family member or relative who provides care * First-ever and unilateral stroke * Willing to participate voluntarily * Aged between 18-75 years * Post-stroke duration longer than 3 months * Stable vital signs * Scoring ≥24 on the Standardized Mini-Mental State Examination (SMMT) or the -Modified Mini-Mental State Examination for Illiterate Individuals (MMSE-E) * Able to understand and speak Turkish 2. Caregivers of Stroke Patients: * Willing to participate in the study * Living with the patient for at least 1 year * Being the primary (main responsible) caregiver and not receiving paid professional caregiving services * Aged 18 years or older * Scoring ≥24 on the Standardized Mini-Mental State Examination (SMMT) or MMSE-E Exclusion Criteria: 1. Stroke Patients: * Presence of severe comorbid conditions * Unwillingness to participate * History of multiple strokes * Bilateral hemiplegia * Presence of major neurological, orthopedic, or rheumatologic disorders affecting the musculoskeletal system other than stroke * Congenital anomalies or amputation causing disability * Uncontrolled arrhythmia, uncontrolled hypertension, or unstable cardiac conditions * Botulinum toxin injection within the last 6 months * Inability to establish cooperation * Presence of neglect, aphasia, or hemianopsia 2. Caregivers of Stroke Patients: * Unwillingness to participate * Living with the patient for less than 1 year * Presence of mental retardation, dementia, or severe psychotic disorders

Inclusion Criteria * Participants must have a diagnosis of World Health Organisation (WHO) Group 1 pulmonary hypertension (PAH) in any of the following subtypes, in accordance with European Society of Cardiology European Respiratory Society (ESC/ERS) Guidelines: * Idiopathic PAH * Heritable PAH * Drug/toxin-induced PAH * Connective tissue disease (CTD)-associated PAH * PAH associated with congenital heart disease-related to simple systemic-to-pulmonary shunt at least 1 year following repair. * PAH diagnosis for at least 3 months prior to Screening. * New York Heart Association (NYHA) or World Health Organization (WHO) functional class II-IV. * Participants must be on stable PAH therapy consisting of 1 to 3 medications from the following classes: * Endothelin receptor antagonists (eg, ambrisentan, bosentan, macitentan) for at least 90 days prior to Screening with the last 30 days on stable dose * Phosphodiesterase type 5 inhibitors (eg, sildenafil, tadalafil) for at least 90 days prior to Screening with the last 30 days on stable dose * Guanylate cyclase stimulator (eg, riociguat) for at least 90 days prior to Screening with the last 30 days on stable dose * Activin signaling inhibitor (e.g., sotatercept) for at least 6 months prior to Screening, with the last 3 months on stable dose and meeting all the following conditions: * no active clinically significant bleeding (eg, epistaxis and gingival bleeding requiring medical interventions) within the past 3 months. * no history of major bleeding events or risks (eg, gastrointestinal or intracranial bleeding) within the past 6 months. * platelet counts ≥100,000 per microlitre (μL) at Screening * For both 6-minute walk tests (6MWTs), the values of 6-minute walk distance (6MWD) should be ≥ 150 and ≤ 450 meters at Screening. * Right heart catheterization (RHC) at Screening (or within 6 months prior to Screening, if available). Prior RHC may be used provided there has been no change in background PAH therapy and doses. The RHC must meet all of the following hemodynamic criteria: * Mean pulmonary arterial pressure (PAP) \>20 millimetre of mercury (mmHg) at rest. * pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) ≤15 mmHg. * pulmonary vascular resistance (PVR) of ≥5 wood units (WU). Exclusion Criteria * Diagnosis of PH WHO Groups 2, 3, 4, or 5, or subtypes of PH WHO Group 1 other than described in inclusion criterion 2 (eg, human immunodeficiency virus (HIV), complex congenital heart disease-associated PAH, portal hypertension-associated PAH, pulmonary veno-occlusive disease, Schistosomiasis associated PAH). * Clinically significant left heart disease, including left-sided valvular disease, left ventricular systolic or diastolic dysfunction, echocardiographic findings suggestive of post-capillary pulmonary hypertension, unstable ischemic heart disease, or unstable arrhythmias. * Evidence of airflow obstruction defined by forced expiratory volume in 1 second (FEV1) per forced vital capacity (FVC) \<0.7. * Evidence of significant restrictive lung disease as evidenced by FVC \<70% predicted normal. * Evidence of chronic thromboembolic disease or recent (within 6 months of Screening) acute pulmonary embolism. * Known hypersensitivity or contraindication to treprostinil or TPIP or TPIP formulation excipients (e.g., mannitol, leucine). * Any other medical or psychological condition including relevant laboratory abnormalities at Screening that, in the opinion of the Investigator, suggest a new and/or insufficiently understood disease and/or may present an unreasonable risk to the study participant as a result of his/her participation in this clinical trial, may impede their ability complete the study or the study assessments or confound the outcomes of the trial. Note: Other protocol-defined inclusion/exclusion criteria may apply.

Inclusion Criteria: 1. Female or male，age 18 to 75. 2. Body mass index (BMI) ≥ 22 kg/m² and ≤ 35 kg/m² at screening. 3. HbA1c of 7.0-10.5 %. 4. Diagnosed with type 2 diabetes mellitus at least 90 days prior to day of screening. 5. Stable daily dose of metformin (at least 1500 mg or maximum tolerated dose≥1000 mg/day) at least 90 days prior to the day of screening. Exclusion Criteria: 1. Family or personal history of Multiple Endocrine Neoplasia Type 2 or Medullary Thyroid Carcinoma. 2. History of pancreatitis (acute or chronic). 3. History of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery). 4. Subjects presently classified as being in New York Heart Association Class IV. 5. Planned coronary, carotid or peripheral artery revascularisation known on the day of screening. 6. Renal impairment defined as Estimated Glomerular Filtration Rate below 60 mL/min/1.73 m\\\^2 as per Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI).

Inclusion Criteria: * Healthy male or female participants； * Age from 18 to 45 years, inclusive； * Body Mass Index (BMI) between 19.0 and 26.0 kg/m² (inclusive). Male participants must weigh at least 50.0 kg, and female participants must weigh at least 45.0 kg； * From the time of signing the informed consent form until 3 months after the last dose, participants must have no plans for pregnancy or sperm donation and must be willing to use effective contraceptive measures； * Voluntarily agrees to participate in the study and signs the informed consent form. Exclusion Criteria: * Any clinically significant abnormalities in laboratory tests or a history of clinically significant diseases, including but not limited to cardiovascular, cerebrovascular, hepatic, renal, respiratory, gastrointestinal, neurological, hematological, immune, oncological, psychiatric, or endocrine/metabolic disorders; * Known history of severe allergies (e.g., allergy to more than 3 allergens, allergies affecting the lower respiratory tract such as allergic asthma, allergies requiring glucocorticoid treatment) or a known history of allergy to any component of the investigational products; * Previous surgery that could affect drug absorption, distribution, metabolism, or excretion (e.g., subtotal gastrectomy), or a history of gastrointestinal, hepatic, or renal disease within the last 6 months that could affect drug absorption or metabolism; * Surgery within 3 months prior to screening or planned surgery during the study period; * Received any vaccination within 1 month prior to screening or plan to receive any vaccination during the study period; * History of infectious disease treated with significant use of antibiotics within 3 months before the first dose, or any infectious disease within 7 days before the first dose; * Presence of gastrointestinal symptoms (e.g., diarrhea, constipation, nausea, vomiting) within 7 days before the first dose, which the investigator deems unsuitable for study participation; * Use of any prescription drugs, over-the-counter drugs, or Chinese herbal medicines within 1 month before the first dose; or use of vitamin products within 2 weeks before enrollment; * History of drug or substance abuse, or a positive alcohol or urine drug screening test; * Intolerance to venipuncture, or a history of fainting in response to needles or blood; * Fasting blood glucose \> 6.1 mmol/L or \< 3.9 mmol/L at screening, and/or a history of hypoglycemia/syncope; * Participation in any interventional clinical trial within 3 months prior to screening; * Blood donation or significant blood loss (\> 200 mL) within 3 months prior to screening; * Pregnant or lactating women; * Weekly alcohol consumption of more than 14 units within 3 months prior to screening, consumption of alcohol within 48 hours before the first dose, or inability to abstain from alcohol during the study; * Smokes more than 5 cigarettes per day within 3 months prior to screening, has smoked within 48 hours before the first dose, or is unable to abstain from smoking during the study; * Excessive daily consumption of tea, coffee, and/or caffeinated beverages within 3 months prior to screening, or consumption of such beverages within 48 hours before the first dose; * Consumption of grapefruit or grapefruit-related citrus fruits (e.g., Seville oranges, pomelos), star fruit, papaya, pomegranate, or their products within 14 days before the first dose; * Glomerular Filtration Rate (GFR) \< 90 mL/min/1.73 m²; * Systolic blood pressure \< 90 mmHg or ≥ 140 mmHg, or diastolic blood pressure \< 50 mmHg or ≥ 90 mmHg at screening; * Inability to comply with the standardized diet (e.g., intolerance to the high-fat meal, lactose intolerance) or has difficulty swallowing; * Plans to or is required to engage in strenuous physical activity or exercise during the study period; * Any other condition that, in the opinion of the investigator, makes the participant unsuitable for inclusion in the study.

Inclusion Criteria * Female participants * High-normal blood pressure values (≥130/85 mmHg) or mild hypertension (140/90 mmHg) with low cardiovascular risk and no current indication for pharmacological therapy * Presence of a non-dipper blood pressure phenotype on 24-hour ambulatory blood pressure monitoring * Absence of antihypertensive pharmacological treatment Exclusion Criteria * History of cardiovascular disease * Diabetes mellitus * Severe chronic diseases * Use of medications affecting blood pressure or heart rate * Known allergy to Nigella sativa or fennel

Inclusion criteria: All participants: * General health based on medical history, physical examination, blood draw, and electrocardiogram * Age 18 to 55 years * Right-handedness (due to potential lateralization effects of left-handed subjects) * Willingness and competence to sign the informed consent form * Normal BMI weight range (18.5-24.9) Specific to healthy subjects: * Psychiatric health based on structured clinical interview for DSM-5 (SCID) * No concomitant medication Specific to anhedonia patients: * Major depressive episode (first or recurrent) based on structured clinical interview for DSM-5 (SCID) and ICD-10 * Fulfilling the ICD-10 diagnostic criterion of anhedonia * No concomitant medication, specifically also free of antidepressants or other psychopharmaceuticals (for at least 2 weeks, 5 weeks for fluoxetin) Exclusion criteria: All participants: * Current or history of neurological disease * Current medical illness requiring treatment * Pregnancy or current breastfeeding * Current or former substance dependency * Any contraindication for MRI * Failure to comply with the study protocol or to follow the instruction of the investigating team * Failure to confirm effective use of contraception in females at least 8 weeks before and after study participation each * First-degree relative with bipolar disorder or schizophrenia Specific to healthy subjects: \- Psychiatric diagnosis Specific to anhedonia patients: \- Psychiatric comorbidities excluding anxiety disorders and/or obsessive-compulsive disorders

Inclusion Criteria: * Study participants aged 18 to 60 years (inclusive of 18 and 60 years), both male and female * Body weight not less than 50 kg. Body Mass Index (BMI) = weight (kg) / height\^2 (m\^2). BMI must be within the range of 19 to 26 kg/m\^2 (inclusive of the limit values) * The study participant is able to communicate well with the research staff, fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial, and sign a written informed consent form * The study participant or their partner has no plans for pregnancy, sperm donation, or egg donation during the study period and for 3 months after drug administration, and must agree to use at least one acceptable effective contraceptive method * During the screening period: 110 mmHg ≤ seated systolic blood pressure (SBP) \< 140 mmHg, 65 mmHg ≤ seated diastolic blood pressure (DBP) \< 90 mmHg, and no orthostatic hypotension. Exclusion Criteria: * Those who smoked more than 5 cigarettes per day on average in the 3 months prior to the trial and are unable to quit smoking during the trial period. * Pregnant or breastfeeding women, or female study participants of childbearing potential with a positive blood pregnancy screening. * Known allergic reaction to angiotensin II receptor antagonists (such as sacubitril/valsartan sodium, alisartan ester, losartan, valsartan) and calcium channel blockers (such as nifedipine, amlodipine), or their excipients; or allergic constitution (multiple drug and food allergies). * Alcoholics or those who frequently consumed alcohol within the 3 months prior to screening, i.e., consuming more than 14 standard alcohol units per week (1 unit alcohol = 360 mL beer or 45 mL spirits with 40% alcohol content or 150 mL wine), or those with a positive alcohol breath test, or those unable to stop using any alcohol-containing products during the trial period. * Those who donated blood or experienced significant blood loss (\>400 mL), used blood products, or received a blood transfusion within the three months prior to screening. * Those who have undergone surgery within 3 months prior to screening or plan to undergo surgery during the study period, or subjects with a history of surgery affecting drug absorption, distribution, metabolism, or excretion. * Those who have been vaccinated within 3 months prior to screening. * History of hypotension, syncope, needle fainting, swallowing difficulties, any gastrointestinal disease affecting drug absorption, or any history of conditions increasing hemorrhagic risk, such as acute gastritis or gastroduodenal ulcers. * Use of any drug that alters hepatic enzyme (CYP3A4) activity or inhibitors of transporters (OAT1/3, OATP1B1/3) within 28 days prior to screening. * Use of any prescription drugs, over-the-counter medications, vitamin products, or herbal remedies within 14 days prior to screening. * Participation in any drug clinical trial and administration of any other investigational drug, or use of investigational products, within 3 months prior to taking the study drug. * Clinically significant abnormalities in vital signs, physical examination, 12-lead electrocardiogram (ECG), or laboratory tests (including complete blood count, urinalysis, blood biochemistry, coagulation profile, and four infectious disease markers) at screening. * Any other disease or medical history considered by the investigator as unsuitable for participation in this study, such as disorders of the central nervous, cardiovascular, digestive, respiratory, urinary, hematopoietic, immune systems, psychiatric conditions, or metabolic abnormalities. * Consumption of chocolate, any caffeine-containing, or xanthine-rich foods or beverages within 48 hours prior to taking the study drug. * History of drug abuse or substance abuse, or a positive urine drug screen at screening. * Those with special dietary habits who cannot comply with the unified dietary requirements, or those with lactose intolerance (e.g., history of diarrhea after drinking milk). * Any other reason considered by the investigator as unsuitable for enrollment.

Inclusion Criteria: Participants must meet all the following criteria and sign an informed consent form (ICF) to be eligible for the study. 1. Patient must be aged 18-75 years old at the time of enrollment. 2. Presented with asthmatic symptoms such as wheezing, shortness of breath, chest tightness and cough ≥2 months prior to enrollment (Day 0), with/without an established asthma diagnosis. Exclusion Criteria: Patients are excluded from the study if any of the following criteria apply: Medical Conditions 1. Respiratory infections within 3 months prior to enrollment (Day 0), including but not limited to: acute bacterial/viral pneumonia, acute bronchitis, Influenza, COVID-19 or acute exacerbation of chronic bronchitis. 2. Current smoker; or cessation from smoking less than 6 months; or cessation smoking for more than 6 months but smoked more than 10 packs/year. 3. History of other chronic respiratory diseases other than asthma, including but not limited to tuberculosis, significant bronchiectasis, established interstitial lung disease, and lung cancer. 4. History of serious comorbidities, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could: 1. Affect the safety of the patient throughout the study, 2. Confound the study results or impact the scientific validity of the data outcome, 3. Impede the patient's ability to complete the entire duration of study. 5. Positive urine pregnancy test, or breastfeeding women, or any women who are planning to become pregnant (current and within 3 months). Prior/Concomitant Therapy 6. ICS-based medication (including ICS, ICS/LABA, ICS/LABA/LAMA) use within 3 months prior to enrollment (Day 0). ICS=inhaled corticosteroids; LABA=long-acting β2 agonists; LAMA=long-acting muscarinic antagonists. Other Exclusions 7. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements. 8. Current participation in another interventional clinical trial.

Inclusion criteria: * Age 20 to35 years * Gestational age 36 weeks * Body mass index (BMI) \<35kg/m2. * Mild preeclampsia Exclusion criteria : * Age \<19 or \>40 years, gestational age \<36 weeks, body mass index (BMI)≥40kg/m2. * Women presenting in emergency delivery. * Patient with other co morbidity sever cardiovascular or central nervous disease.

Inclusion Criteria: * Healthy male or female participants； * Age from 18 to 45 years, inclusive； * Body Mass Index (BMI) between 19.0 and 26.0 kg/m² (inclusive). Male participants must weigh at least 50.0 kg, and female participants must weigh at least 45.0 kg； * From the time of signing the informed consent form until 3 months after the last dose, participants must have no plans for pregnancy or sperm donation and must be willing to use effective contraceptive measures； * Voluntarily agrees to participate in the study and signs the informed consent form. Exclusion Criteria: * Any clinically significant abnormalities in laboratory tests or a history of clinically significant diseases, including but not limited to cardiovascular, cerebrovascular, hepatic, renal, respiratory, gastrointestinal, neurological, hematological, immune, oncological, psychiatric, or endocrine/metabolic disorders; * Known history of severe allergies (e.g., allergy to more than 3 allergens, allergies affecting the lower respiratory tract such as allergic asthma, allergies requiring glucocorticoid treatment) or a known history of allergy to any component of the investigational products; * Previous surgery that could affect drug absorption, distribution, metabolism, or excretion (e.g., subtotal gastrectomy), or a history of gastrointestinal, hepatic, or renal disease within the last 6 months that could affect drug absorption or metabolism; * Surgery within 3 months prior to screening or planned surgery during the study period; * Received any vaccination within 1 month prior to screening or plan to receive any vaccination during the study period; * History of infectious disease treated with significant use of antibiotics within 3 months before the first dose, or any infectious disease within 7 days before the first dose; * Presence of gastrointestinal symptoms (e.g., diarrhea, constipation, nausea, vomiting) within 7 days before the first dose, which the investigator deems unsuitable for study participation; * Use of any prescription drugs, over-the-counter drugs, or Chinese herbal medicines within 1 month before the first dose; or use of vitamin products within 2 weeks before enrollment; * History of drug or substance abuse, or a positive alcohol or urine drug screening test; * Intolerance to venipuncture, or a history of fainting in response to needles or blood; * Fasting blood glucose \> 6.1 mmol/L or \< 3.9 mmol/L at screening, and/or a history of hypoglycemia/syncope; * Participation in any interventional clinical trial within 3 months prior to screening; * Blood donation or significant blood loss (\> 200 mL) within 3 months prior to screening; * Pregnant or lactating women; * Weekly alcohol consumption of more than 14 units within 3 months prior to screening, consumption of alcohol within 48 hours before the first dose, or inability to abstain from alcohol during the study; * Smokes more than 5 cigarettes per day within 3 months prior to screening, has smoked within 48 hours before the first dose, or is unable to abstain from smoking during the study; * Excessive daily consumption of tea, coffee, and/or caffeinated beverages within 3 months prior to screening, or consumption of such beverages within 48 hours before the first dose; * Consumption of grapefruit or grapefruit-related citrus fruits (e.g., Seville oranges, pomelos), star fruit, papaya, pomegranate, or their products within 14 days before the first dose; * Glomerular Filtration Rate (GFR) \< 90 mL/min/1.73 m²; * Systolic blood pressure \< 90 mmHg or ≥ 140 mmHg, or diastolic blood pressure \< 50 mmHg or ≥ 90 mmHg at screening; * A positive test result at screening for any of the following: Human Immunodeficiency Virus antibody, Treponema pallidum antibody, Hepatitis B surface antigen, or Hepatitis C virus antibody; * Inability to comply with the standardized diet (e.g., intolerance to the high-fat meal, lactose intolerance) or has difficulty swallowing; * Plans to or is required to engage in strenuous physical activity or exercise during the study period; * Any other condition that, in the opinion of the investigator, makes the participant unsuitable for inclusion in the study.

Inclusion Criteria: 1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial. 2. Community-dwelling 3. Male or female 4. Age ≥ 65 at the time of signing informed consent 5. Glycated hemoglobin levels of ≥7% (i.e., A1c levels high enough to see intervention-related changes and increase eligibility for recruitment, but can exercise safely) 6. Eligible for the Ontario Drug Benefit (inadequate glycemic control and on max tolerated dose of metformin or metformin contraindicated or inappropriate) 7. Score \>24/30 on the Mini-Mental State Exam (MMSE) 8. Score \>6/8 on the Lawton Instrumental Activities of Daily Living Scale (IADL) 9. Have visual acuity of \>20/40 with or without corrective lenses 10. Speak and understand English fluently 11. Complete the Physical Activity Readiness Questionnaire (PAR-Q+) and obtain physician clearance to start a supervised exercise program 12. Comfortable with a blood draw 13. Not currently engaging in structured resistance exercise more than once per week Exclusion Criteria: 1. Have a medical condition for which semaglutide or exercise is contraindicated 2. Use of a GLP-1 receptor agonist in the past 6 months (i.e., offers removal of Semaglutide from the system as it has a half-life of around 1 week; thus, 8-10 weeks are required for a washout. 3\) Have engaged regularly (\>1/week) in aerobic or RE within the past 6 months 4) Have a neurodegenerative disease (i.e., dementia) or psychiatric condition 5) Have had untreated depression in the past 6 months (6) Have experienced a recent vascular incident (i.e., stroke, myocardial infarction in the last 6 months.) (7) Have severe peripheral neuropathy, an active foot wound, or severe musculoskeletal/joint disease (8) Active or untreated retinopathy (9) Taking psychotropic medications (excluding those for the treatment of depression)

Inclusion Criteria: \- Subjects with asthma diagnosis grade according to FEV 60%-80% Exclusion Criteria: * Pregnancy * Previous breathing exercise training * Severe comorbidity * Patients with short life expectancy * subjects with Severe physical impairments * Subjects with Mental disease

Inclusion Criteria: * Men or women over the age of 18 * Psychiatric diagnosis: * Presenting a depressive episode characterised according to DSM-5 criteria * MADRS score greater than or equal to 20, indicating moderate to severe depression * Indication and prescription of a course of tDCS treatment consisting of 20 sessions of 30 minutes at 2mA, at a rate of 2 sessions per day * Drug treatment: o Failure of a maximum of 1 or 2 antidepressants taken successively or in combination for the current episode * Psychiatric follow-up: Receiving medical follow-up by a psychiatrist or referring physician * Ability to understand and cooperate: * Having a smartphone, computer or tablet (with internet connection and Bluetooth) to use the digital interface required to perform remote tDCS * Be deemed capable of understanding the nature of the study and participating in clinical follow-up * Informed consent: Have given written consent to participate in the research, after receiving oral and written information about the study. * Social affiliation: Be affiliated with a social security system Exclusion Criteria: * Psychiatric or neurological diagnoses: * Chronic psychotic disorders or history of schizophrenia * Progressive neurological disorders (unstabilised epilepsy, brain tumour, recent stroke, severe head injury) * History or current treatment of neuromodulation * Any history of tDCS treatment, whether carried out in a clinical or research setting * Current treatment or history of rTMS and ECT sessions for the current episode * Presence of an active vagus nerve stimulation implant * Presence of a high risk of suicide. A risk of suicide will be considered high if the score on item 10 of the MADRS scale ("Suicidal Thoughts") is 4 or higher, and/or if there is active suicidal ideation accompanied by clinically identified intent or a plan * Addiction and substance use: Current substance use disorder other than nicotine or caffeine * Psychiatric comorbidities that may interfere with study participation, including: understanding information, adherence to the protocol, and completing CBT sessions. * Recent change in curative psychotropic treatment (antidepressant, mood stabiliser including lithium and anticonvulsants, mood-stabilising antipsychotic) in the month prior to inclusion. * Medical contraindication to stimulation: * Presence of a metallic or electronic implant in the skull or chest (pacemaker, neurostimulator, cochlear implant) * Skin lesion, irritation or wound on the electrode contact areas * History of epileptic seizures not related to an identified cause or not stabilised for more than 12 months * Current pregnancy or breastfeeding * Women of childbearing age without effective contraception (hormonal or medical device) * A severe and/or progressive somatic condition requiring ongoing medical care that would interfere with participation in the study. * Limited ability to participate: * A significant cognitive impairment or sensory deficit that prevents understanding of instructions * Inability to safely perform tDCS at home, as defined by at least one of the following: * inability to understand or recall essential instructions regarding procedure and safety; * inability to perform, following initial guidance, the essential steps for setting up and starting the device; * lack of the minimum material conditions required at home to conduct the sessions. * Special legal or social situation: * Patients under guardianship, curatorship or judicial protection * Privation of liberty by judicial or administrative decision, Presence of a functional limitation to the independent performance of tDCS

Inclusion Criteria: * • adult patients of Kazakh nationality aged 18 to 74 years * diagnosis of T2DM established according to ADA criteria and documented in medical records * disease duration ≤5 years * absence of ketoacidosis episodes within the last 6 months Exclusion Criteria: * positive anti-glutamic acid decarboxylase antibodies (anti-GAD65); * acute or chronic infections affecting metabolic status within the previous 4 weeks; * any history of malignant neoplasms; * pregnancy or lactation; * previously diagnosed type 1 diabetes mellitus or other specific types of diabetes; * severe decompensated chronic diseases; * conditions associated with systemic fibrosis (e.g., liver cirrhosis or autoimmune diseases); * refusal to participate.

Inclusion Criteria 1. Age ≥18 years (≥40 years for COPD patients). 2. Clinical diagnosis of asthma, ABPA, bronchiectasis, OSAS, or COPD according to established criteria. 3. PRISm patients (post-BD FEV1/FVC ≥70% and FEV1 \<80% predicted) 4. Smoking controls: ≥10 pack-years, normal lung function, no chronic respiratory symptoms. 5. Healthy controls: normal lung function, FeNO \<20 ppb, total IgE \<100 IU/mL, no chronic disease, smoking \<10 pack-years, no immunosuppressant use within 3 months. Exclusion Criteria 1. Patients with severe respiratory diseases other than those included in the study, such as pulmonary embolism, pneumothorax, pulmonary hypertension, interstitial lung disease, or active lung cancer. 2. Patients with severe systemic diseases that may interfere with study completion, such as myocardial infarction, severe arrhythmia, hepatic insufficiency, renal insufficiency, hematological disorders, or malignancy. 3. Patients with an acute exacerbation within 4 weeks before enrollment, or systemic use of antibiotics, antifungal drugs, immunosuppressive agents, cytotoxic agents, or corticosteroids (except for long-term maintenance therapy) 4. Pregnant or lactating women. 5. Patients with poor compliance as judged by the investigators. 6. Subjects currently participating in other clinical studies.

Inclusion Criteria: * Adults aged ≥19 years * Patients diagnosed with stage 1 hypertension according to clinical guidelines * Patients who are newly prescribed Olmetec® or Olmetec Plus® in routine -clinical practice * Patients who are able to undergo ambulatory blood pressure monitoring (ABPM) * Patients who voluntarily agree to participate and provide written informed consent Exclusion Criteria: * Patients with secondary hypertension * Patients with severe hypertension requiring immediate pharmacological i-ntervention * Patients with known hypersensitivity to olmesartan medoxomil, hydrochlorothiazide, or any component of the study drugs * Patients who are pregnant, planning to become pregnant, or breastfeeding * Patients with severe renal impairment or severe hepatic impairment * Patients who are unable to comply with study procedures, including ABPM * Patients who are deemed inappropriate for participation by the investigator

Inclusion Criteria: * suspected Alzheimer's disease * type 2 diabetes (group A) * able and willing to comply with study protocoil´´l Exclusion Criteria: * type 2 diabetes (group B and C) * significant brain disease apart from dementia (group A and B) * significant vascular or neurological disease (group C) * active cancer treatment * history of alcohol or drug abuse * severe claustrophobia * pregnancy or breastfeeding

Inclusion Criteria: Breast cancer patients with an indication for axillary lymphadenectomy according to the multidisciplinary team: * cN0 with positive sentinel lymph node biopsy (pN+) requiring axillary lymphadenectomy: cT3; More than two axillary macrometastases; or patients undergoing mastectomy without indication for adjuvant radiotherapy * cN1: Primary surgery; or after neoadjuvant therapy without complete axillary response and/or positive TAD (ypN+) * cN2: Primary surgery; or after neoadjuvant therapy in luminal tumors and/or without complete axillary response in triple-negative or HER2-positive tumors, and/or positive TAD (ypN+) Exclusion Criteria: * Patients with prior axillary radiotherapy * Patients with suspected metastatic involvement based on palpation of ARM lymph nodes during the surgical procedure * Patients participating in other studies whose primary objective depends on local axillary treatment * Patients unwilling to participate in the study

Inclusion Criteria: * Age ≥ 18 years and enrolled as a college student * Symptoms of mild to moderate depression * Receiving treatment for depression or willing to receive treatment during study participation * Generally in good physical health * On a stable dose of any medication affecting weight, metabolism, or mental health Exclusion Criteria: * Elevated risk for suicide * Inability to participate safely, as determined by the study physician * Lifetime diagnosis of bipolar disorder, schizophrenia, or post-traumatic stress disorder * Current eating disorder (e.g., bulimia, anorexia nervosa, binge eating) * Current alcohol or substance use disorder * Shift work outside of class schedule in the past 30 days * Pregnancy or lactation * Treatment with an investigational drug for depression or participation in another study requiring modification of diet